Improvement of atopic dermatitis and IgA nephropathy in a patient treated by dupilumab

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F21%3A43920886" target="_blank" >RIV/00216208:11120/21:43920886 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064173:_____/21:N0000202

Výsledek na webu

<a href="https://doi.org/10.1111/dth.14708" target="_blank" >https://doi.org/10.1111/dth.14708</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/dth.14708" target="_blank" >10.1111/dth.14708</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Improvement of atopic dermatitis and IgA nephropathy in a patient treated by dupilumab

Popis výsledku v původním jazyce

Atopic dermatitis is a chronic multifactorial inflammatory skin disease with a prevalence of 1-3% in adults and 15 to 20% in the world&apos;s pediatric population, that poses a significant burden on patients&apos; quality of life. In recent years, there has been increasing evidence of multiple comorbidities associated with atopic dermatitis including not only atopic conditions such as hay fever or asthma, but also ocular complications, cardiovascular and autoimmune diseases. Dupilumab is the first approved fully human monoclonal antibody for the treatment of moderate to severe atopic dermatitis. It blocks IL-4 receptor-signaling of both IL-4 and IL-13. We describe a case of a 31-year-old male patient who has suffered from severe atopic dermatitis since early childhood.

Název v anglickém jazyce

Improvement of atopic dermatitis and IgA nephropathy in a patient treated by dupilumab

Popis výsledku anglicky

Atopic dermatitis is a chronic multifactorial inflammatory skin disease with a prevalence of 1-3% in adults and 15 to 20% in the world&apos;s pediatric population, that poses a significant burden on patients&apos; quality of life. In recent years, there has been increasing evidence of multiple comorbidities associated with atopic dermatitis including not only atopic conditions such as hay fever or asthma, but also ocular complications, cardiovascular and autoimmune diseases. Dupilumab is the first approved fully human monoclonal antibody for the treatment of moderate to severe atopic dermatitis. It blocks IL-4 receptor-signaling of both IL-4 and IL-13. We describe a case of a 31-year-old male patient who has suffered from severe atopic dermatitis since early childhood.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30216 - Dermatology and venereal diseases

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Dermatologic Therapy

ISSN

1396-0296

e-ISSN

—

Svazek periodika

34

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

2

Strana od-do

"e14708"

Kód UT WoS článku

000619117800213

EID výsledku v databázi Scopus

2-s2.0-85099099476